Septerna, Inc, situated in South San Francisco, CA, is dedicated to pioneering a new era of GPCR drug discovery. The company focuses on unlocking the full potential of G protein-coupled receptor (GPCR) drug targets to develop impactful new medicines across therapeutic areas.
Powered by their proprietary Native Complex Platform™, Septerna is at the forefront of discovering innovative ways to drug GPCRs. Their industrial-scale platform is designed to unlock challenging GPCRs, leading to the development of a pipeline of oral small molecule drug candidates.
Septerna boasts a world-class team of drug hunters, GPCR experts, and drug developers committed to advancing cutting-edge science. Their collaboration-driven approach and relentless focus on developing novel oral small molecule GPCR-targeted programs set them apart in the industry.
Generated from the website content
